SOURCE-LINKED STUDY SUMMARY
The Discovery and Development of Liraglutide and Semaglutide.
What was studied?
This review traces the discovery and development of liraglutide and semaglutide, rather than reporting a new clinical trial.
What changed?
Albumin binding helped extend drug action while retaining receptor activity. The review describes pancreatic and brain receptor effects on glucose control and weight, and cardiovascular benefits in diabetes; the cardiovascular mechanism remained uncertain.
Who was studied?
It discusses human and non-human research, including people with type 2 diabetes and obesity.
Studied exposure
Not extracted or not reported in this source.
What remains uncertain?
Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.3389/fendo.2019.00155